Notably, NDDs consistently exhibit characteristic FA metabolic network disturbances, including reduced SCFA levels, dysregulated n-3/n-6 ratios, and accumulated LPO end-products, which collectively provide novel therapeutic targets for NDD modulation. Here, LPO is linked to Neurodevelopmental delay.